全文获取类型
收费全文 | 6783篇 |
免费 | 584篇 |
国内免费 | 20篇 |
专业分类
耳鼻咽喉 | 54篇 |
儿科学 | 125篇 |
妇产科学 | 180篇 |
基础医学 | 800篇 |
口腔科学 | 116篇 |
临床医学 | 818篇 |
内科学 | 1541篇 |
皮肤病学 | 66篇 |
神经病学 | 673篇 |
特种医学 | 222篇 |
外科学 | 833篇 |
综合类 | 176篇 |
一般理论 | 11篇 |
预防医学 | 558篇 |
眼科学 | 153篇 |
药学 | 556篇 |
中国医学 | 9篇 |
肿瘤学 | 496篇 |
出版年
2023年 | 42篇 |
2022年 | 63篇 |
2021年 | 145篇 |
2020年 | 91篇 |
2019年 | 129篇 |
2018年 | 177篇 |
2017年 | 121篇 |
2016年 | 128篇 |
2015年 | 139篇 |
2014年 | 188篇 |
2013年 | 268篇 |
2012年 | 390篇 |
2011年 | 399篇 |
2010年 | 241篇 |
2009年 | 206篇 |
2008年 | 354篇 |
2007年 | 382篇 |
2006年 | 319篇 |
2005年 | 331篇 |
2004年 | 316篇 |
2003年 | 302篇 |
2002年 | 222篇 |
2001年 | 185篇 |
2000年 | 195篇 |
1999年 | 167篇 |
1998年 | 59篇 |
1997年 | 60篇 |
1996年 | 44篇 |
1995年 | 48篇 |
1994年 | 43篇 |
1993年 | 45篇 |
1992年 | 117篇 |
1991年 | 111篇 |
1990年 | 97篇 |
1989年 | 88篇 |
1988年 | 81篇 |
1987年 | 79篇 |
1986年 | 75篇 |
1985年 | 84篇 |
1984年 | 83篇 |
1983年 | 66篇 |
1982年 | 54篇 |
1980年 | 43篇 |
1979年 | 69篇 |
1978年 | 63篇 |
1977年 | 63篇 |
1976年 | 50篇 |
1975年 | 38篇 |
1974年 | 43篇 |
1973年 | 48篇 |
排序方式: 共有7387条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
S Shuman E M Kane S G Morham 《Proceedings of the National Academy of Sciences of the United States of America》1989,86(24):9793-9797
Site-directed mutagenesis of the vaccinia virus gene encoding a type I DNA topoisomerase implicates Tyr-274 as the active-site residue that forms a covalent adduct with DNA during cycles of DNA-strand breakage and reunion. Replacement of Tyr-274 by phenylalanine results in loss of the ability of the enzyme to relax negatively supercoiled DNA as well as to form the covalent DNA-protein intermediate. Substitution of phenylalanine for tyrosine at nine other sites in the protein has no apparent effect on enzyme activity. Amino acid sequence alignment reveals Tyr-274 to be homologous to Tyr-727 and Tyr-771, respectively, of the type I topoisomerases from Saccharomyces cerevisiae and Saccharomyces pombe; Tyr-727 and Tyr-771 have been shown to represent the active-site tyrosines of those enzymes. Sequence comparison of the active-site regions defines a motif Ser-Lys-Xaa-Xaa-Tyr common to the viral and cellular type I topoisomerases, including the human enzyme. 相似文献
5.
Chad G. Ball Andrew W. Kirkpatrick Matthew Smith Robert H. Mulloy Leonard Tse Ian B. Anderson 《European journal of trauma and emergency surgery》2007,33(5):550-552
Abstract We report a case of SMV injury in a critically ill patient. The patient was a 19-year-old woman involved in a motor vehicle
collision. Her injuries included grade II splenic and renal lacerations, devascularized and lacerated right and transverse
colon, a transected transverse mesocolon, a massive shear injury of her abdominal wall, and two partial SMV transections.
At initial damage control laparotomy, the SMV was ligated, the devascularized bowel resected and a temporary abdominal closure
applied. At re-operation, a mesocaval shunt using saphenous vein was employed. The shunt failed and the patient required a
saphenous vein jump graft. Although visceral vascular injuries are rare, ligation of the SMV in a damage control situation
is acceptable. This case study is the first to discuss appropriate treatment when interruption to a patient's collateral visceral
venous drainage limits the surgeon’s ability to ligate. In these situations, bypass shunts may be successful. 相似文献
6.
Kai-Hang Yiu MBBS Chung-Wah Siu MBBS Chu-Pak Lau MD Kathy L.F. Lee MBBS Hung-Fat Tse MD 《Heart rhythm》2007,4(2):221-223
We report a case of successful transvenous, catheter-based, cavotricuspid isthmus ablation for treatment of atrial flutter using microwave energy. Microwave energy was delivered at 900–930 MHz using 21 W of power. Bidirectional cavotricuspid isthmus conduction block was achieved by microwave ablation without any patient discomfort or complication during the procedure. Our initial experience suggests that transcatheter microwave ablation is feasible for the cure of typical atrial flutter. 相似文献
7.
D S Rao R Antonelli K R Kane J E Kuhn C Hetnal 《Henry Ford Hospital medical journal》1991,39(1):41-44
Coexistent primary hyperparathyroidism and monoclonal gammopathy, although rare, has been reported previously by a number of investigators. We report four patients with such an occurrence who were seen between 1976 and 1988. Another patient with primary hyperparathyroidism also had multiple myeloma and was in remission for 12 years. These patients represent approximately 1% of the 386 patients with primary hyperparathyroidism seen during the same 12-year period. Although several mechanisms have been proposed to explain this concurrence, we believe it is the result of a chance occurrence. A review of the literature, an estimate of the chance occurrence of coincidental monoclonal gammopathy, benign or malignant, in patients with primary hyperparathyroidism, and some practical implications of this interesting coexistence are presented. 相似文献
8.
9.
10.
Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers. 总被引:4,自引:0,他引:4
The pharmacokinetics of fluvastatin, a potent inhibitor of hydroxymethylglutaryl-CoA reductase and thus cholesterol synthesis, have been studied in 24 normal male volunteers who received [3H] fluvastatin in three different studies: a single-dose study using oral doses of 2 or 10 mg, an absolute bioavailability study using doses of 2 mg intravenously or 10 mg orally, and a multiple-dose study using 40 mg orally once daily for 6 days. Serial blood and plasma samples and complete urine and feces were collected and analyzed for total radioactivity as well as for intact fluvastatin. Fluvastatin was rapidly and almost completely (greater than 90%) absorbed from the gastrointestinal tract, although the estimated bioavailability from the 2- and 10-mg doses was only 19 to 29% because of extensive first-pass metabolism. Fluvastatin pharmacokinetics appeared to be linear over the 2- to 10-mg dose range, as indicated by dose-proportional blood levels of total radioactivity and the parent drug. Absorbed fluvastatin was completely metabolized before excretion, the biliary/fecal route being the major excretory pathway. The recovery of radioactivity after a single dose was virtually complete within 120 hours. The terminal half-lives of fluvastatin and total radioactivity averaged 0.5 to 1 hour and 55 to 71 hours, respectively, whereas the total body clearance of fluvastatin was 0.97 L/hour/kg. Repeated oral administration of 40-mg doses of [3H]fluvastatin resulted in no time-related change in pharmacokinetic characteristics, but this dose yielded greater than proportional increases in circulating levels of the parent drug, thus suggesting a saturable first-pass effect on fluvastatin.(ABSTRACT TRUNCATED AT 250 WORDS) 相似文献